Ifosfamide in pediatric malignant solid tumors

Cancer Chemotherapy and Pharmacology
C B PrattJ Wilimas

Abstract

Ifosfamide/mesna was given to 97 patients who had malignant solid tumors diagnosed before they were 21 years of age. Patients received 1.6 g/m2 ifosfamide daily x 5, given i.v. over 15 min, followed by 400 mg/m2 i.v. mesna at 15 min and 4 and 6 h after ifosfamide. Responses were noted in patients with osteosarcoma, Ewing's sarcoma, rhabdomyosarcoma and other soft-tissue sarcomas, rhabdoid tumor, neuroblastoma, Wilms' tumor, primitive neuroectodermal tumor, retinoblastoma, germ-cell tumors, and B-cell lymphoma. Toxicity included mild to moderate nausea and vomiting, transient, reversible myelosuppression, transient elevations of serum blood urea nitrogen (BUN) and creatinine and liver enzymes, infections, and self-limiting neurotoxicity characterized by changes in mental status, motor dysfunction, cranial nerve palsy, cerebellar dysfunction, and seizures. Neurotoxic symptoms were generally seen in patients who had previously received cisplatin. Ifosfamide is an important alkylating agent that should be combined with other agents in phase II and III trials. Alternate dose schedules should also be investigated.

Citations

Dec 9, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J S Whelan
Jun 1, 2012·Pediatric Blood & Cancer·Angela D Trobaugh-Lotrario, James H Feusner
Apr 1, 1994·Cancer Treatment Reviews·M K Tuxen, S W Hansen
Jan 27, 2011·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Yng-Tay ChenJiunn-Wang Liao
Aug 10, 2007·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·Premila AbrahamEmila Sugumar
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael S IsakoffRichard Gorlick
Oct 26, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefano FerrariUNKNOWN Italian and Scandinavian Sarcoma Groups
Jul 29, 2015·Biomedit︠s︡inskai︠a︡ khimii︠a︡·S A CherepanovV P Chekhonin
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S PappoH E Grier
Jul 29, 2005·Canadian Journal of Physiology and Pharmacology·Katarina AleksaGideon Koren
Apr 16, 2019·Pediatric Hematology and Oncology·Jassada BuaboonnamKleebsabai Sanpakit
Jan 1, 1992·Medical and Pediatric Oncology·A CangirP Salmonsen
Jun 1, 2021·Expert Opinion on Pharmacotherapy·Cristina Meazza, Sebastian Dorin Asaftei

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.